Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: Report of a Veterans Affairs Cooperative Study

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 11, Issue 2, 1996, Pages 142-150

  Simberkoff, Michael S ^a,b   Hartigan, Pamela M ^d   Hamilton, John D ^a   Day, Philip L ^e   Diamond, Gigi R ^a   Dickinson, Gordon M ^a   Drusano, George L ^f   Egorin, Merrill J ^a   Lance George, W ^b   Gordin, Fred M ^a   Hawkes, Clifton A ^g   Jensen, Peter C ^c   Klimas, Nancy G ^a   Labriola, Ann M ^a   Lahart, Christopher J ⁱ   O'Brien, William A ^b   Oster, Charles N ^h   Weinhold, Kent J ^g   Wray, Nelda P ⁱ   Zolla Pazner, Susan B ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VA Coordinating Center   (United States)

^e VA Cooperative Studies Program Clinical Research Pharmacy   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

^g DUKE UNIVERSITY   (United States)

^h USUHS/Walter Reed Army Hospital   (United States)

ⁱ NONE

Author keywords

Human immunodeficiency virus; Opportunistic infections; Survival; Zidovudine

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; DIDANOSINE; PENTAMIDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCYSTIS CARINII;

EID: 1842458302     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199602010-00005     Document Type: Article

References (30)

1. Sande MA, Carpenter CCJ, Cobbs G, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1993;270:2583-9.
2. U.S. Department of Health and Human Services, Public Health Service. Evaluation and management of early HIV infection. Agency for Health Care Policy and Research (AHCPR) Publication No. 94-0572. (Clinical Practice Guidelines No. 7), 1994.
3. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebocontrolled trial. JV Engl J Med 1987;317:185-91.
4. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of mildly symptomatic human immunodeficiency virus type l (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990;112:727-37.
5. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9.
6. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-6.
7. Graham NM, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Eng J Med 1992;326:1037-42.
8. Concorde Coordinating Committee. Concorde MRC/ANRS randomized double-blind controlled trail of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
9. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994;272:437-42.
10. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus later zidovudine in symptomatic human immunodeficiency virus infection: results of a Veterans Affairs Cooperative Study. N Eng J Med 1992;326:437-43.
11. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(Suppl 1S):1-16.
12. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977;35:1-39.
13. Kalbfleisch JD, Prentice RG. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980;10-19, 70-142.
14. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Eng J Med 1993;329:297-303.
15. Caliendo AM, Hirsch MS. Combination therapy for infection due to hurrian immunodeficiency virus, type 1. Clin Infect Dis 1994;18:516-24.
16. Kahn JO, Lagakos SE, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Eng J Med 1992;327:581-7.
17. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and nontreated with zidovudine. JAMA 1994;271:1088-92.
18. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP, and the Multicenter AIDS Cohort Study. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994;7:287-95.
19. Ionnidis JPA, Cappelleri JC, Lau J, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: A meta-analysis. Ann Intern Med 1995;122:856-66.
20. Wei X, Gosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
21. Ho DD, Neuman AU, Perelson AS, et al. Rapid turnover of plama virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
22. Larder BA, Darby G, Richmann DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
23. Boucher CAB, Tersmette M, Lange JMA, et al. Zidovudine sensitivity of human immunodeficiency viruses from highrisk, symptom-free individuals during therapy. Lancet 1990;336:585-90.
24. Tersmette M, Lange JMA, De Goede REY, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989;1:983-5.
25. St. Clair MH, Hartigan PM, Andrews JC, et al. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr 1993;6:891-7.
26. Sutin DG, Rose DN, Mulvihill M, Taylor B. Survival of elderly patients with transfusion-related acquired immunodeficiency syndrome. J Am Geriatr Soc 1993;41:214-6.
27. Blum S, Singh TP, Fordyce EJ, et al. Trends in survival among persons with acquired immunodeficiency syndrome in New York City, the experience of the first decade of the epidemic. Am J Epidemiol 1994;139:351-61.
28. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Eng J Med 1994;330:657-2.
29. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995;122;24-32.
30. Bartlett JG. Zidovudine now or later? N Eng J Med 1993;329:351-2.